Physician profile
George Kovach
NPI 1982663985
$5,003.95
in general payments reported to CMS, 2019-2025
37 companies · $1,002 in 2025
The $1,002 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.00 · 2021: $631 · 2022: $918 · 2023: $712 · 2024: $1,645 · 2025: $1,002.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,358.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $505.49 | 2021-2025 | Enhertu, Injectafer |
| Astrazeneca Pharmaceuticals LP | $385.36 | 2021-2025 | Tagrisso, Enhertu |
| Beigene USA, INC. | $361.22 | 2021-2023 | Brukinsa |
| Genzyme Corporation | $343.97 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $323.14 | 2022-2024 | Pomalyst, Opdivo |
| Myriad Genetic Laboratories, INC. | $312.50 | 2024 | Myrisk |
| Novartis Pharmaceuticals Corporation | $266.62 | 2023-2025 | |
| Janssen Biotech, INC. | $209.00 | 2024-2025 | Darzalex, Tecvayli, Rybrevant |
| Genentech USA, INC. | $195.80 | 2019-2025 | Tecentriq, Gazyva, Columvi |
| Regeneron Healthcare Solutions, INC. | $155.97 | 2025 | Libtayo, Lynozyfic |
| Jazz Pharmaceuticals INC. | $150.00 | 2023 | Zepzelca |
| Gilead Sciences, INC. | $146.45 | 2022-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $142.68 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| Sobi, INC | $134.15 | 2024-2025 | |
| Mirati Therapeutics, INC. | $131.15 | 2023-2024 | Krazati |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $122.29 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $120.26 | 2024-2025 | Fruzaqla, Hyqvia |
| Aveo Pharmaceuticals, INC. | $119.07 | 2022-2025 | |
| G1 Therapeutics, INC. | $117.45 | 2022 | |
| Seagen INC. | $91.04 | 2021 | |
| Celgene Corporation | $87.45 | 2024 | Reblozyl |
| Genmab U.S., INC. | $82.92 | 2024 | Epkinly |
| Pharmaessentia USA Corporation | $65.71 | 2024-2025 | Besremi |
| Recordati_rare_diseases_inc. | $51.70 | 2025 | Enjaymo |
| Incyte Corporation | $51.10 | 2025 | Jakafi |
| Servier Pharmaceuticals LLC | $43.91 | 2024 | |
| Pfizer INC. | $39.79 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $36.80 | 2024 | Onivyde |
| Eisai INC. | $36.76 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.08 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $31.80 | 2024-2025 | Keytruda, Welireg |
| Taiho Oncology, INC. | $30.64 | 2024-2025 | |
| Adaptive Biotechnologies Corporation | $19.09 | 2024 | Clonoseq |
| Exelixis INC. | $16.05 | 2024 | Cabometyx |
| Geron Corporation | $15.56 | 2025 | Rytelo |
| Stemline Therapeutics INC. | $13.50 | 2025 | Orserdu |
| Syndax Pharmaceuticals, INC. | $13.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Kovach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.